“Many urologists in large group practices are doing genetic testing, especially for their high-risk patients,” says Emmanuel S. Antonarakis, MD.
Emmanuel S. Antonarakis, MD, discusses the frequency of genetic testing in urology clinics for the management of patients with prostate cancer. He is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation.
Expert explains everything urologists need to know on genomic testing
November 15th 2022All patients with prostate cancer, except for those with low-risk or very low-risk localized disease, should be tested for germline mutations, and somatic testing should be done in all patients with metastatic disease as there are therapeutic implications, according to Emmanuel S. Antonarakis, MD.
Novel biomarker emerges for salvage RT approach in biochemically recurrent prostate cancer
November 11th 2022A higher score on PORTOS, an expression signature of 24 DNA damage repair and immune pathway genes, predicted improved response to dose-intensified salvage radiotherapy after radical prostatectomy in patients with biochemically recurrent prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512